Evidence map›Paper›PMID 36054160›Full record

ArticleAnnals of neurology2022

Ganaxolone versus Phenobarbital for Neonatal Seizure Management.

Suzanne L Miller, Laura Bennet, Amy E Sutherland, Yen Pham, Courtney McDonald, Margie Castillo-Melendez, Beth J Allison, Jamie Mihelakis, Ilias Nitsos, Ben J Boyd and 8 more

Open access · hybridAbstract read
In one paragraph

Article in Annals of neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
4.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 2 countries.

Suzanne L MillerRitchie Centre, Department of Obstetrics and Gynaecology, Monash University and Hudson Institute of Medical Research, Clayton, Victoria, Australia.
Laura BennetDepartment of Physiology, University of Auckland, Auckland, New Zealand.
Amy E SutherlandRitchie Centre, Department of Obstetrics and Gynaecology, Monash University and Hudson Institute of Medical Research, Clayton, Victoria, Australia.
Yen PhamRitchie Centre, Department of Obstetrics and Gynaecology, Monash University and Hudson Institute of Medical Research, Clayton, Victoria, Australia.
Courtney McDonaldRitchie Centre, Department of Obstetrics and Gynaecology, Monash University and Hudson Institute of Medical Research, Clayton, Victoria, Australia.
Margie Castillo-MelendezRitchie Centre, Department of Obstetrics and Gynaecology, Monash University and Hudson Institute of Medical Research, Clayton, Victoria, Australia.
Beth J AllisonRitchie Centre, Department of Obstetrics and Gynaecology, Monash University and Hudson Institute of Medical Research, Clayton, Victoria, Australia.
Jamie MihelakisRitchie Centre, Department of Obstetrics and Gynaecology, Monash University and Hudson Institute of Medical Research, Clayton, Victoria, Australia.
Ilias NitsosRitchie Centre, Department of Obstetrics and Gynaecology, Monash University and Hudson Institute of Medical Research, Clayton, Victoria, Australia.
Ben J BoydMonash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
Jonathan J HirstSchool of Biomedical Sciences and Pharmacy, University of Newcastle, Newcastle, New South Wales, Australia.
David W WalkerSchool of Health and Biomedical Sciences, RMIT University, Bundoora, Victoria, Australia.
Rodney W HuntDepartment of Paediatrics, Monash University, Clayton, Victoria, Australia.
Graham JenkinRitchie Centre, Department of Obstetrics and Gynaecology, Monash University and Hudson Institute of Medical Research, Clayton, Victoria, Australia.
Flora WongRitchie Centre, Department of Obstetrics and Gynaecology, Monash University and Hudson Institute of Medical Research, Clayton, Victoria, Australia.
Atul MalhotraRitchie Centre, Department of Obstetrics and Gynaecology, Monash University and Hudson Institute of Medical Research, Clayton, Victoria, Australia.
Michael C FaheyRitchie Centre, Department of Obstetrics and Gynaecology, Monash University and Hudson Institute of Medical Research, Clayton, Victoria, Australia.
Tamara YawnoRitchie Centre, Department of Obstetrics and Gynaecology, Monash University and Hudson Institute of Medical Research, Clayton, Victoria, Australia.ORCID 0000-0002-4257-3814
Hudson Institute of Medical Research · AUMonash University · AURMIT University · AUUniversity of Auckland · NZUniversity of Newcastle Australia · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveSeizures are more common in the neonatal period than at any other stage of life. Phenobarbital is the first-line treatment for neonatal seizures and is at best effective in approximately 50% of babies, but may contribute to neuronal injury. Here, we assessed the efficacy of phenobarbital versus the synthetic neurosteroid, ganaxolone, to moderate seizure activity and neuropathology in neonatal lambs exposed to perinatal asphyxia.

methodsAsphyxia was induced via umbilical cord occlusion in term lambs at birth. Lambs were treated with ganaxolone (5mg/kg/bolus then 5mg/kg/day for 2 days) or phenobarbital (20mg/kg/bolus then 5mg/kg/day for 2 days) at 6 hours. Abnormal brain activity was classified as stereotypic evolving (SE) seizures, epileptiform discharges (EDs), and epileptiform transients (ETs) using continuous amplitude-integrated electroencephalographic recordings. At 48 hours, lambs were euthanized for brain pathology.

resultsAsphyxia caused abnormal brain activity, including SE seizures that peaked at 18 to 20 hours, EDs, and ETs, and induced neuronal degeneration and neuroinflammation. Ganaxolone treatment was associated with an 86.4% reduction in the number of seizures compared to the asphyxia group. The total seizure duration in the asphyxia+ganaxolone group was less than the untreated asphyxia group. There was no difference in the number of SE seizures between the asphyxia and asphyxia+phenobarbital groups or duration of SE seizures. Ganaxolone treatment, but not phenobarbital, reduced neuronal degeneration within hippocampal CA1 and CA3 regions, and cortical neurons, and ganaxolone reduced neuroinflammation within the thalamus.

interpretationGanaxolone provided better seizure control than phenobarbital in this perinatal asphyxia model and was neuroprotective for the newborn brain, affording a new therapeutic opportunity for treatment of neonatal seizures. ANN NEUROL 2022;92:1066-1079.

Indexed as

Asphyxia NeonatorumEpilepsyPregnanoloneAnimalsAnimals, NewbornAnticonvulsantsDisease Models, AnimalHumansInfant, NewbornPhenobarbitalSeizuresSheepAnticonvulsantsganaxolonePhenobarbitalPregnanolone

Identifiers

PMID36054160
PMCPMC9828769
OpenAlexW4294176582

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.